Senhwa Biosciences, Inc. has reached a major milestone its recent clinical collaboration with BeOne Medicines to explore combination therapy with its marketed PD-1 inhibitor in the field of cold tumor treatment. The company’s investigational drug Pidnarulex (CX-5461) will be evaluated in combination with the antibody-drug conjugate (ADC), Trastuzumab Deruxtecan (Enhertu), in a Phase 1b clinical trial.  The study is designed for HER2-positive solid tumors and breast cancer patien...